Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus ONMEL.
CHILDREN'S MOTRIN vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
50 mg orally twice daily for 14 days
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category C
Category C
NSAID
NSAID